Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Liver Neoplasms 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Specimen Handling 6Paclitaxel 6Magnetic Resonance Spectroscopy 5Nivolumab 4Carboplatin 4Biopsy 4pembrolizumab 2olaparib 2ceralasertib 2Taxes 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pamiparib 1durvalumab 1cobimetinib 1cediranib 1cabozantinib 1belinostat 1atezolizumab 1X-Rays 1Tissue Banks 1TIC10 compound 1Ipilimumab 1Immunoglobulin G 1Ifosfamide 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × trastuzumab deruxtecan × Gynecologic × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡